Related Experiment Video

Updated: Jun 10, 2026

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

Making the best of PARP inhibitors in ovarian cancer

Susana Banerjee1, Stan B Kaye, Alan Ashworth

  • 1The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.

Nature Reviews. Clinical Oncology
|August 12, 2010
PubMed

Insights

Poly(ADP-ribose)polymerase (PARP) inhibitors show promise for treating BRCA-mutated cancers. Maximizing their benefit in ovarian cancer requires exploring new trial strategies, drug combinations, and predictive biomarkers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • PARP inhibitors are effective in cancers with BRCA1/BRCA2 mutations.
  • This strategy leverages synthetic lethality targeting DNA repair pathways.
  • High-grade ovarian cancer often has a poor prognosis and BRCA alterations.

Purpose of the Study:

  • To explore strategies for maximizing the therapeutic benefit of PARP inhibitors in ovarian cancer.
  • To identify key factors for successful clinical application of PARP inhibitors in this disease.

Main Methods:

  • Review of current therapeutic approaches and evidence.
  • Consideration of synthetic lethality principles in cancer treatment.
  • Analysis of potential biomarkers for PARP inhibitor response.

Main Results:

  • PARP inhibitors demonstrate significant promise for BRCA-mutated ovarian cancers.
  • BRCA1/BRCA2 mutations or BRCA1 silencing are potentially common in ovarian cancer.
  • Optimizing PARP inhibitor efficacy necessitates innovative clinical trial designs.

Conclusions:

  • Novel therapeutic trial strategies and drug combinations are essential for maximizing PARP inhibitor benefit.
  • Incorporating robust predictive biomarkers is crucial for patient selection and treatment success.
  • Further research is needed to fully realize the potential of PARP inhibitors in ovarian cancer treatment.

More Related Videos

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...